Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rang in aandelen #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Aandeelprijs
$22.26
Laatst gesynchroniseerd: 2024-03-22
Marktkapitalisatie
$553.40M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Graphite Bio, Inc. (GRPH)

Categorie

Aandelsplitsingen voor Graphite Bio, Inc. (GRPH)
Het aandeel Graphite Bio, Inc. (symbool: GRPH) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 31, 2026.
Eén aandeel GRPH dat vóór Aug 31, 2026 werd gekocht, staat nu gelijk aan 0 aandelen GRPH.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH